Targeting IL-6 pathway seems so promising in JIA that another antibody targeting IL-6R, sarilumab, is in phase II trials for polyarticular JIA and systemic JIA (ClinicalTrialsGov NCT02776735; NCT02991469). The gene discussed is IL6R; the disease is juvenile idiopathic arthritis.